^
Association details:
| Biomarker: | SDK1-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | foritinib (SAF-189) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
Published date:
03/04/2022
Excerpt:
In this study, we discovered a rare ALK rearrangement type (SDK1-ALK) in a Chinese lung adenocarcinoma patient who responded well to ALK inhibitor SAF-189s….This is the first case of SDK1-ALK fusion with an excellent response to an ALK inhibitor...
DOI:
10.3389/fonc.2022.860060
